Report

Deeply undervalued, high growth stock

Occasionally even professionals lament about ‘the one that got away’. However investing is a bit like surfing, ‘you don't need to catch all the big waves to still have a great time’.

Luckily for investors, the ClearStar ship has not sailed yet, despite the shares (at 49p) trading at a 56% discount to our 115p/share valuation. This unjustified gap between price (ie what you pay) and value (what it is worth) is likely to close at some point. Especially as the firm continues to deliver new business wins, double digit organic growth, improving operating leverage and higher margins.

Indeed today, it announced another significant contract win (min $0.4m in 2020). This time with a leading facilities management (FM) group, to provide screening for people entering its 120,000 locations across North America serving numerous industries.

Fine, but what about the numbers? Well, we reckon 2019 results were in line with expectations - $300k of adjusted EBITDA (pre SBPs) on $23.0m of revenues - and hence make no change to our forecasts. An estimated 72% of turnover is now derived from CLSU’s two strategic growth engines (ie Medical & Direct), that together expanded by >26% (all organic).
Moreover looking ahead, this latest customer endorsement, alongside ongoing pipeline conversion, generates robust visibility, with the company anticipated to be cashflow neutral/positive in 2020, on sales & EBITDA of $26.0m (13.0% LFL) & $1,260k respectively.

Add all this up, and we think ClearStar remains a deeply undervalued, high growth stock - priced at a compelling 1x 2020 EV/sales vs 3x for recent M&A activity.
Underlyings
Ideagen

Ideagen is a supplier of information management software to regulated industries. Co. supplies Governance, Risk and Compliance solutions principally to the Healthcare, Transport, Aerospace & Defense, Life Sciences, Manufacturing and Financial Services sectors.

Wolters Kluwer NV

Wolters Kluwer operates through four divisions: Health is a global provider of information for medical and health professionals; Financial & Compliance Services is a U.S. provider risk management, compliance, finance, and audit professionals the services they need to optimize risk and business performance, and ensure compliance with local, regional, and global regulation; Tax & Accounting is a provider of tax, accounting, and audit information, and services; and Legal & Regulatory provides customers with expert content, software, and services in the areas of law, business, and regulatory compliance in Europe, North America and Asia Pacific.

Provider
Equity Development
Equity Development

​Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.

Analysts
Paul Hill

Other Reports on these Companies
Other Reports from Equity Development

ResearchPool Subscriptions

Get the most out of your insights

Get in touch